Market Analysis
The global drug device combination market share is predicted to grow at a whopping
7.2% CAGR over the assessment period 2023-2032. Drug-device combination
products relate a drug with that of a medical device to bridge various
regulatory frameworks (device or drug). This can be a single product having
several components such as drug-eluting stents, transdermal patches or products
that are separately packed yet intended for use exclusively with a definite
counterpart. Drug-device combination products offer an array of advantages
namely targeted drug delivery, improved patient compliance, controlled drug
administration and minimal side effects. Owing to its increased sophistication
and different advantages, drug device combination products are widely adopted
all across the medical sector.
There are
plentiful factors that is boosting the growth of the drug device combination market. These factors as per the Market
Research Future (MRFR) report include increasing incidences of urology,
prostate cancer, diabetic neuropathy, colorectal cancer, respiratory problems
and cardiovascular diseases, growing healthcare expenditure, increasing
awareness of market products, growing geriatric population, technological
advancements in the drug-device combination product, increase in homebased
healthcare market, high market potential, and increase in healthcare
expenditure. On the contrary, side effects, existence of low-income countries,
soaring price of products, strict government rules for the approval of these
devices and errors and post-complications leading to various product recalls
are factors that may deter drug device
combination market growth.
Key Players
Drug device combination market
players profiled in the industry include Zimmer Holding, Inc, Wright Medical
Group, Inc., Stryker Corporation, St. Jude Medical Inc, Smith & Nephew Plc,
Covidien Ltd, Cook Critical Care, Inc., C.R. BARD, Inc., Boston Scientific
Corporation, Biotronik, Biometrix Medical, Biomet Orthopedics, Inc, AlloSource,
Abbott Laboratories, 3M, and others.
Market Segmentation
MRFR
report provides an extensive segmental analysis of the drug device combination market outlook on the basis of product, application and
end-users.
Based on
product, it is segmented into advanced wound care products, catheter and
others. Catheter is again segmented into wound drainage catheter,
thermodilution catheters, oximetry catheters, cardiovascular catheters,
urological catheters, antimicrobial catheter and others. Advanced wound care
products are again segmented into photodynamic therapy, drug eluting stents,
antibiotic bone cements, bone graft substitutes and antibiotic wound care. Bone
graft substitutes is again segmented into cell-based bone graft substitutes,
allograft-based bone graft substitutes, ceramic based bone graft substitute and
others.
Based on
application, the drug device combination market
is segmented into ophthalmic treatment, wound care, antimicrobial applications,
bone treatment, peripheral arterial disease, non-cardiovascular treatments,
tachycardia management, coronary angioplasty and others.
Based on end-users, it is segmented into academic and
research organization, ambulatory centers, hospitals and clinics and others.
Regional Analysis
By
region, the drug device combination market insights covers growth opportunities and latest
trends across the Americas, Europe, Asia Pacific and Middle East and Africa. Of
these, the Americas will sway the market over the assessment period owing to
increasing incidence of cardiovascular diseases, presence of key market
players, developed healthcare sector in Canada and the US, high healthcare
expenditure and suitable reimbursement policies. In the European region, the drug device combination market will have the second
major share due to huge patient pool, presence of developed economies,
increasing awareness about the device and presence of healthcare infrastructure
that is well-developed. In the APAC region, the drug device combination market
is expected to grow at the fastest pace owing to growing support from the
government for foreign investments, growing healthcare sector and growing
penetration of market players here. On the other hand, the drug device
combination market in the Middle East and Africa will have minimal share in the
market owing to low per capita income and presence of poor economies. The
Middle East is anticipated to have a major share in the drug device combination
market owing to presence of developed economies such as Dubai, Saudi Arabia,
United Arab Emirates and others and increasing funds made by the government in
the healthcare sector.
About US:
Market Research Future (MRFR),
enable customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of
Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New
York,
New York 10013
United States of America
